Company Profile
Monopar Stock Price, News & Analysis
- Ticker:
- MNPR
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
110.33 USD (+0.42%)
Close
Last updated: July 27, 2026
410M USD
Market cap
Why the stock is moving
As of Jul 27, 2026, MNPR closed up 0.42% at $110.33. No new same-company headline was identified in the current news window.
Company overview
Business overview
Monopar Therapeutics is a biotechnology company focused on oncology and rare disease, with a history of targeting difficult indications. Its narrative is built around using a concentrated pipeline to create value in high-unmet-need settings.
Geographic Base and Sector Classification
Monopar is headquartered in the United States and listed on NASDAQ. It sits in small-cap specialty biopharma.
Business Model Characteristics
The company depends on clinical progress, strategic prioritization, and capital management across a narrow program set. Investors typically watch proof-of-concept data and financing runway.
Position Within the Biotechnology Landscape
Monopar occupies a catalyst-sensitive niche within biotech. The stock is driven by whether its focused development approach can produce clear differentiated value.
Future catalysts
What matters most for Monopar from here is ALXN1840 and tiomolibdate choline. That matters because the company is now talking about NDA Submission on Track for Mid-2026 In April 2026, Monopar presented new analyses from the randomized controlled Phase 3 FoCus trial of ALXN1840 (tiomolibdate choline, TMC) at.... That is the piece most likely to shape sentiment in the near term.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK
GSK · Source: GSK plc
- 02
Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
LEGN · Source: Legend Biotech Corporation
- 03
- 04
- 05
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
KYMR · Source: Kymera
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Monopar (MNPR)?
Monopar (MNPR) most recently closed at 110.33 USD, a +0.42% move versus the previous session.
What is the market cap of Monopar (MNPR)?
Monopar currently has a market capitalization of 410M USD on BioPharmSignal.
What does Monopar do?
Monopar Therapeutics is a biotechnology company focused on oncology and rare disease, with a history of targeting difficult indications. Its narrative is built around using a concentrated pipeline to create value in high-unmet-need settings.
On which exchange is MNPR stock listed?
Monopar (MNPR) is associated with NASDAQ, United States, Biopharma.
What is Monopar?
What matters most for Monopar from here is ALXN1840 and tiomolibdate choline.
Which conditions is Monopar targeting with Monopar?
Monopar is associated with oncology, rare disease based on its company overview and current catalyst commentary.
How does Monopar describe recent progress with Monopar?
What matters most for Monopar from here is ALXN1840 and tiomolibdate choline.
What is Therapeutics?
Monopar Therapeutics is a biotechnology company focused on oncology and rare disease, with a history of targeting difficult indications.